High-Intensity Statins Underused With Atherosclerotic Cardiovascular Disease

Authors say findings show gaps between practice and guideline-based care

Adobe Stock

TUESDAY, Sept. 19, 2023 (HealthDay News) -- Among patients with atherosclerotic cardiovascular disease (ASCVD), high-intensity statins are underutilized in routine care, according to a study published online Aug. 2 in Circulation: Cardiovascular Quality and Outcomes.

Ann Marie Navar, M.D., Ph.D., from University of Texas Southwestern Medical Center in Dallas, and colleagues examined use of statins and other lipid-lowering therapy (LLT) and changes in low-density lipoprotein cholesterol (LDL-C) among patients with ASCVD. The analysis included electronic health record-derived data from outpatient visits for 322,153 patients with ASCVD (Cerner Real-World Data from 92 U.S. health systems 2017 through 2018).

The researchers found that 76.1 percent of patients were on statins, with only 39.4 percent on high-intensity statins. Compared with women, men were more likely to receive high-intensity statins (multivariable-adjusted odds ratio [OR], 1.34). Lower odds of statin use were seen with increasing age (OR, 0.79 per five-year increase at 60 years). Compared with patients with coronary heart disease, patients with peripheral artery disease (OR, 0.40) and cerebrovascular disease (OR, 0.75) had lower odds of using high-intensity statins. Most patients (61.3 percent) at baseline had elevated LDL-C (≥70 mg/dL), including 59.8 percent of those on low/moderate-intensity statins and 76.1 percent on no statin. At one year, only 45.3 percent achieved an LDL-C <70 mg/dL. Nonstatin LLT use was low. Among patients on no statin or low/moderate-intensity statin at baseline, at one year, 14.8 and 13.4 percent, respectively, were on high-intensity statins.

"Concerted efforts are needed to address therapeutic inertia for lipid management in patients with ASCVD," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Lori Solomon

Lori Solomon

Medically reviewed by Mark Arredondo, M.D.

Published on September 19, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ